Physician profile
Ruth Diamond
NPI 1013255975
$1,980.02
in general payments reported to CMS, 2019-2025
18 companies · $193 in 2025
The $193 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $51.84 · 2022: $71.57 · 2023: $253 · 2024: $1,411 · 2025: $193.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,857.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,856.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $339.61 | 2021-2024 | Keytruda, Welireg, Lynparza |
| Novartis Pharmaceuticals Corporation | $281.63 | 2023-2025 | |
| Pfizer INC. | $194.09 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $187.82 | 2024-2025 | Reblozyl, Opdivo, Opdualag |
| Astrazeneca Pharmaceuticals LP | $156.02 | 2024-2025 | Enhertu, Calquence |
| Astellas Pharma US INC | $135.08 | 2023-2024 | Xtandi, Xospata |
| Lilly USA, LLC | $125.70 | 2023-2024 | Verzenio, Jaypirca, Cyramza |
| Springworks Therapeutics, INC. | $96.05 | 2024-2025 | Ogsiveo |
| Seagen INC. | $94.10 | 2022-2023 | Tivdak, Padcev |
| Servier Pharmaceuticals LLC | $77.46 | 2023-2025 | |
| Gilead Sciences, INC. | $60.05 | 2022-2025 | Trodelvy |
| Janssen Biotech, INC. | $55.00 | 2024 | Rybrevant |
| Eisai INC. | $48.57 | 2023-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $44.93 | 2024 | Fruzaqla |
| Daiichi Sankyo INC. | $22.87 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Blueprint Medicines Corporation | $22.36 | 2024 | |
| Amgen INC. | $21.89 | 2022 | |
| Genentech USA, INC. | $16.79 | 2024 | Columvi, Lunsumio, Polivy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ruth Diamond listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.